Table 2. The association between SOCS3 expression and the clinical features of NSCLC patients.
| Variables | Low SOCS3 (n=226) | High SOCS3 (n=174) | P |
|---|---|---|---|
| Age (years), n | 0.502 | ||
| ≥55 | 105 | 80 | |
| <55 | 121 | 94 | |
| Sex, n | 0.341 | ||
| Male | 98 | 71 | |
| Female | 128 | 103 | |
| Smoker, n | 0.301 | ||
| Non-smoker | 68 | 64 | |
| Ever smoker | 81 | 52 | |
| Current smoker | 77 | 58 | |
| TNM stage, n | 0.003 | ||
| IIIB | 85 | 90 | |
| IV | 141 | 84 | |
| Differentiation, n | 0.036 | ||
| Low | 131 | 117 | |
| High | 95 | 57 | |
| Treatment response, n | 0.001 | ||
| Good | 66 | 99 | |
| Poor | 160 | 75 | |
SOCS3, suppressor of cytokine signaling 3; NSCLC, non-small cell lung cancer; TNM, tumor-node-metastases.